CONMED (NYSE:CNMD) Releases FY 2025 Earnings Guidance

by · The Cerbat Gem

CONMED (NYSE:CNMD – Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 4.480-4.530 for the period, compared to the consensus EPS estimate of 4.500. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CNMD. JPMorgan Chase & Co. decreased their target price on shares of CONMED from $58.00 to $52.00 and set a “neutral” rating for the company in a research report on Thursday, November 6th. Piper Sandler decreased their price target on CONMED from $68.00 to $55.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Bank of America lowered their target price on shares of CONMED from $65.00 to $52.00 and set a “neutral” rating for the company in a report on Monday, December 8th. Wells Fargo & Company reduced their price objective on shares of CONMED from $57.00 to $47.00 and set an “equal weight” rating for the company in a research report on Thursday, November 6th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of CONMED in a research report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, CONMED presently has a consensus rating of “Hold” and an average target price of $53.67.

Get Our Latest Report on CNMD

CONMED Stock Up 1.3%

CONMED stock opened at $40.17 on Thursday. The company has a quick ratio of 0.95, a current ratio of 2.10 and a debt-to-equity ratio of 0.85. The company has a market capitalization of $1.24 billion, a P/E ratio of 19.60, a P/E/G ratio of 2.59 and a beta of 0.98. The firm has a 50 day moving average price of $43.25 and a 200-day moving average price of $48.59. CONMED has a twelve month low of $38.32 and a twelve month high of $74.70.

CONMED (NYSE:CNMD – Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.03. The business had revenue of $337.93 million during the quarter, compared to analyst estimates of $334.76 million. CONMED had a return on equity of 14.22% and a net margin of 4.75%.CONMED’s revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.05 earnings per share. CONMED has set its FY 2025 guidance at 4.480-4.530 EPS. As a group, equities analysts predict that CONMED will post 4.35 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CNMD. Wasatch Advisors LP bought a new stake in CONMED during the third quarter valued at $47,026,000. Dimensional Fund Advisors LP boosted its position in shares of CONMED by 19.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,296,776 shares of the company’s stock valued at $60,984,000 after acquiring an additional 214,126 shares during the last quarter. Millennium Management LLC bought a new stake in CONMED during the third quarter valued at approximately $9,239,000. Two Sigma Investments LP increased its holdings in shares of CONMED by 150.3% in the 3rd quarter. Two Sigma Investments LP now owns 164,437 shares of the company’s stock worth $7,733,000 after buying an additional 98,729 shares during the last quarter. Finally, Qube Research & Technologies Ltd raised its position in shares of CONMED by 268.5% during the 3rd quarter. Qube Research & Technologies Ltd now owns 104,838 shares of the company’s stock valued at $4,931,000 after buying an additional 76,386 shares in the last quarter.

About CONMED

(Get Free Report)

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.

Featured Stories